Indian Consensus Guidelines for the Management of Pancreatic Cancer

Viraj Lavingia; Shruti Gohel; Shailesh Shrikhande; Sujith K. Mullapally; Anant Ramaswamy; Vineet Talwar; Fen Saj; Tanvi Sood; Anu R. I.; Munita Menon; Shalini Singh; Senthil Rajappa; Thomas Seufferlein; Eileen O'Reilly; Bhawna Sirohi

doi:10.1055/s-0045-1811946

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1811946

ISMPO Guidelines

Indian Consensus Guidelines for the Management of Pancreatic Cancer

Authors

Viraj Lavingia

¹Department of Medical Oncology, Shalby Hospital, Ahmedabad, Gujarat, India
Shruti Gohel

²Department of Medical Oncology, HCG Cancer Center, Vadodara, Gujarat, India
Shailesh Shrikhande

³Tata Memorial Hospital, Mumbai, Maharashtra, India
Sujith K. Mullapally

⁴Department of Medical Oncology, Apollo Proton Center, Chennai, India
Anant Ramaswamy

⁵Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
Vineet Talwar

⁶Department of Medical Oncology, Rajiv Gandhi Cancer Institute, Delhi, India
Fen Saj

⁷Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas, United States
Tanvi Sood

⁸Department of Medical Oncology, Paras Health, Gurugram, Haryana, India
Anu R. I.

⁹Department of Applied Biomedical Sciences, L-Università ta′ Malta, Malta
Munita Menon

¹⁰Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
Shalini Singh

¹¹Department of Radiation Oncology, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India
Senthil Rajappa

¹²Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital, Hyderabad, India
Thomas Seufferlein

¹³Department of Internal Medicine, Gastroenterology, Endocrinology, Nephrology, Nutrition and Metabolism, Ulm University Hospital, Ulm, Germany
Eileen O'Reilly

¹⁴Memorial Sloan Kettering Cancer Center, New York, United States
Bhawna Sirohi

¹⁵Department of Medical Oncology, BALCO Medical Centre, Raipur, Chhattisgarh, India

Abstract

Pancreatic cancer needs a multidisciplinary approach to treatment. These consensus statements encompass all aspects of treatment of pancreatic cancer within the Indian context. This article outlines consensus-based Indian guidelines for pancreatic cancer (PC), created by a national panel of 39 experts using NCCN and ESMO frameworks. Recommendations were systematically developed via evidence review, expert discussion, and conflict-of-interest exclusions. Guidance covers standardized diagnostic workup, risk stratification and multidisciplinary management involving surgical oncology, medical oncology and radiation oncology. Tumor subtypes (resectable, borderline resectable, locally advanced) determine treatment pathways: upfront surgery for eligible patients and neoadjuvant therapy for downstaging, as appropriate. Preferred regimens for advanced/metastatic disease are outlined. Recommendations are tailored to Indian practice, integrating resource stratification and local access issues. Each guideline is graded for evidence strength and consensus level as per ESMO standards. Emphasis on surveillance and early integrated palliative care aims to optimize patient outcomes. These evidence-based guidelines seek to standardize and elevate PC care across diverse settings in India.

Keywords

guideline - medical oncology - pancreatic cancer treatment

Volltext

Referenzen

References
1 Gaidhani RH, Balasubramaniam G, Gaidhani RH, Balasubramaniam G. An epidemiological review of pancreatic cancer with special reference to India. Indian J Med Sci 2021; 73 (01) 99-109
2 Pancreatic Adenocarcinoma. NCCN Guidelines Version 1.2025. 2024. Accessed September 4, 2025 at: https://www.nccn.org/home/member-
3 Conroy T, Pfeiffer P, Vilgrain V. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (11) 987-1002
4 ESMO Clinical Practice Guidelines. Methodology [cited 2024 Dec 31]. Accessed September 4, 2025 at: https://www.esmo.org/guidelines/esmo-guidelines-methodology
5 Takeshita K, Kutomi K, Haruyama T. et al. Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol 2010; 83 (994) 823-830
6 Farrell JJ, Fernández-del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology 2013; 144 (06) 1303-1315
7 Hu X, Li X, Wang P, Cai J. The role of FAPI PET imaging in pancreatic cancer: a meta-analysis compared with 18F-FDG PET. Acad Radiol 2024
8 Hamano H, Kawa S, Horiuchi A. et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344 (10) 732-738
9 Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24 (18) 2897-2902
10 Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol 2021; 56 (08) 713-721
11 Klein AP, Brune KA, Petersen GM. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64 (07) 2634-2638
12 Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25 (11) 1417-1422
13 Sawhney MS, Calderwood AH, Thosani NC. et al; Prepared by: ASGE Standards of Practice Committee. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc 2022; 95 (05) 817-826
14 Goggins M, Overbeek KA, Brand R. et al; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69 (01) 7-17
15 Amin MB, Greene FL, Edge SB. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67 (02) 93-99
16 Al-Hawary MM, Francis IR, Chari ST. et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 2014; 270 (01) 248-260
17 Valls C, Andía E, Sanchez A. et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002; 178 (04) 821-826
18 Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (07) 1727-1733
19 Hartwig W, Strobel O, Hinz U. et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20 (07) 2188-2196
20 Shrikhande SV, Barreto SG, Sirohi B. et al. Indian Council of Medical Research Consensus Document for the management of pancreatic cancer. Indian J Med Paediatr Oncol 2019; 40 (01) 9-14
21 van der Gaag NA, Rauws EAJ, van Eijck CHJ. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362 (02) 129-137
22 Fietkau R, Grützmann R, Wittel UA. et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 ± trial. Strahlenther Onkol 2021; 197 (01) 8-18
23 Ye C, Sadula A, Ren S. et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol 2020; 86 (06) 731-740
24 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18 (01) 2-11
25 Tan E, Song J, Lam S, D'Souza M, Crawford M, Sandroussi C. Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: a systematic review and meta-analysis. Int J Surg 2019; 72: 59-68
26 Yamada M, Sugiura T, Okamura Y. et al. Clinical implication of node-negative resectable pancreatic cancer. Ann Surg Oncol 2021; 28 (04) 2257-2264
27 Oweira H, Petrausch U, Helbling D. et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol 2017; 23 (10) 1872-1880
28 Labori KJ, Bratlie SO, Biörserud C. et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol 2023; 41 (17, Suppl): LBA4005-LBA4005
29 Uson Junior PLS, Dias E Silva D, de Castro NM. et al. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials. ESMO Open 2023; 8 (01) 100771
30 Jang JY, Kang MJ, Heo JS. et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014; 259 (04) 656-664
31 Delpero JR, Bachellier P, Regenet N. et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 2014; 16 (01) 20-33
32 Delpero JR, Boher JM, Sauvanet A. et al. Pancreatic adenocarcinoma with venous involvement: Is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. Ann Surg Oncol 2015; 22 (06) 1874-1883
33 Bockhorn M, Uzunoglu FG, Adham M. et al; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014; 155 (06) 977-988
34 Mitchem JB, Hamilton N, Gao F, Hawkins WG, Linehan DC, Strasberg SM. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg 2012; 214 (01) 46-52
35 Korrel M, Vissers FL, van Hilst J. et al; International Minimally Invasive Pancreatic Resection Trialists Group. Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trials. HPB (Oxford) 2021; 23 (03) 323-330
36 de Rooij T, van Hilst J, van Santvoort H. et al; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg 2019; 269 (01) 2-9
37 de Rooij T, van Hilst J, Bosscha K. et al; Dutch Pancreatic Cancer Group. Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials 2018; 19 (01) 1
38 Tol JAMG, Gouma DJ, Bassi C. et al; International Study Group on Pancreatic Surgery. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014; 156 (03) 591-600
39 Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA. ‘Artery-first’ approaches to pancreatoduodenectomy. Br J Surg 2012; 99 (08) 1027-1035
40 Loos M, Kester T, Klaiber U. et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg 2022; 275 (04) 759-768
41 Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
42 Iacobuzio-Donahue CA, Fu B, Yachida S. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27 (11) 1806-1813
43 Khorana AA, Mangu PB, Berlin J. et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2017; 35 (20) 2324-2328
44 Liao WC, Chien KL, Lin YL. et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14 (11) 1095-1103
45 Oettle H, Neuhaus P, Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310 (14) 1473-1481
46 Neoptolemos JP, Stocken DD, Bassi C. et al; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304 (10) 1073-1081
47 Neoptolemos JP, Palmer DH, Ghaneh P. et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389 (10073): 1011-1024
48 Conroy T, Castan F, Lopez A. et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 2022; 8 (11) 1571-1578
49 Palmer DH, Jackson R, Springfeld C. et al. Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 Phase III trial. J Clin Oncol 2025; 43 (10) 1240-1253
50 Tempero MA, Pelzer U, O'Reilly EM. et al; APACT Investigators. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol 2023; 41 (11) 2007-2019
51 Halle-Smith JM, Hall L, Daamen LA. et al. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol 2021; 47 (09) 2248-2255
52 Cloyd JM, Heh V, Pawlik TM. et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med 2020; 9 (04) 1129
53 Ghanem I, Lora D, Herradón N. et al. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open 2022; 7 (03) 100485
54 Kunzmann V, Siveke JT, Algül H. et al; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP Investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (02) 128-138
55 Ahmad SA, Duong M, Sohal DPS. et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg 2020; 272 (03) 481-486
56 Ghaneh P, Palmer D, Cicconi S, Halloran C, Psarelli E, Rawcliffe C. et al. ESPAC-5F: Four arm, prospective, multicentre, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol 2020 38. (15, Suppl); doi: doi.org/10.1200/JCO.2020.38.15_suppl.4505
57 Versteijne E, Suker M, Groothuis K. et al; Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol 2020; 38 (16) 1763-1773
58 Chawla A, Shi Q, Ko AH. et al. Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol 2023; 41 (16, Suppl): TPS4204-TPS4204
59 Neoptolemos JP, Stocken DD, Dunn JA. et al; European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234 (06) 758-768
60 Corsini MM, Miller RC, Haddock MG. et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26 (21) 3511-3516
61 Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol 2013; 19 (42) 7461-7471
62 Zhong J, Patel K, Switchenko J. et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 2017; 123 (18) 3486-3493
63 Balaban EP, Mangu PB, Khorana AA. et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34 (22) 2654-2668
64 Hammel P, Huguet F, van Laethem JL. et al; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 Randomized Clinical Trial. JAMA 2016; 315 (17) 1844-1853
65 Abrams RA, Winter KA, Goodman KA. et al. NRG oncology/RTOG 0848: results after adjuvant chemotherapy +/− chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol 2024; 42 (16, Suppl): 4005-4005
66 Rehman H, Chi J, Hakim N. et al. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therap Adv Gastroenterol 2020; 13: 1756284820974912
67 Puleo F, Maréchal R, Demetter P. et al. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21 (08) 2281-2293
68 Fudalej M, Kwaśniewska D, Nurzyński P. et al. New treatment options in metastatic pancreatic cancer. Cancers (Basel) 2023; 15 (08) 2327
69 Burris III HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (06) 2403-2413
70 Heinemann V, Quietzsch D, Gieseler F. et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24 (24) 3946-3952
71 Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20 (15) 3270-3275
72 Cunningham D, Chau I, Stocken DD. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27 (33) 5513-5518
73 Conroy T, Desseigne F, Ychou M. et al; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
74 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18) 1691-1703
75 Pusceddu S, Ghidini M, Torchio M. et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel) 2019; 11 (04) 484
76 Moore MJ, Goldstein D, Hamm J. et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25 (15) 1960-1966
77 Wainberg ZA, Melisi D, Macarulla T. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023; 402 (10409): 1272-1281
78 Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?. World J Gastroenterol 2014; 20 (09) 2224-2236
79 Oettle H, Riess H, Stieler JM. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32 (23) 2423-2429
80 Gill S, Ko YJ, Cripps C. et al. PANCREOX: a randomized Phase iii study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34 (32) 3914-3920
81 Sonbol MB, Firwana B, Wang Z. et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Cancer 2017; 123 (23) 4680-4686
82 Sun K, Mylavarapu C, Crenshaw A. et al. Pancreatic head vs pancreatic body/tail cancer: Are they different?. World J Gastrointest Oncol 2022; 14 (03) 716-723
83 Lowery MA, Kelsen DP, Stadler ZK. et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011; 16 (10) 1397-1402
84 Golan T, Hammel P, Reni M. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381 (04) 317-327
85 Hu ZI, Shia J, Stadler ZK. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 2018; 24 (06) 1326-1336
86 Maio M, Ascierto PA, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938
87 Terrero G, Datta J, Dennison J. et al. Ipilimumab/Nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol 2022; 8 (06) 1-3
88 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378 (08) 731-739
89 Meric-Bernstam F, Makker V, Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial. J Clin Oncol 2024; 42 (01) 47-58
90 Salama AKS, Li S, Macrae ER. et al. Dabrafenib and Trametinib in Patients With Tumors With BRAF^V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol 2020; 38 (33) 3895-3904
91 Bekaii-Saab TS, Spira AI, Yaeger R. et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol 2022; 40 (4, Suppl): 519-519
92 Damanakis AI, Ostertag L, Waldschmidt D. et al. Proposal for a definition of “oligometastatic disease in pancreatic cancer”. BMC Cancer 2019; 19 (01) 1261
93 Puckett Y, Eskander MF, Aquina CT, Pawlik TM. Is there a role for resection of oligometastatic disease in pancreatic ductal adenocarcinoma?. J Cancer Metastasis Treat 2020; 6: 44
94 De Simoni O, Scarpa M, Tonello M. et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers (Basel) 2020; 12 (11) 1-14
95 Hackert T, Niesen W, Hinz U. et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017; 43 (02) 358-363
96 Downs-Canner S, Zenati M, Boone BA. et al. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015; 112 (01) 80-85
97 Lee PJ, Podugu A, Wu D, Lee AC, Stevens T, Windsor JA. Preoperative biliary drainage in resectable pancreatic cancer: a systematic review and network meta-analysis. HPB (Oxford) 2018; 20 (06) 477-486
98 Nabi Z, Reddy DN. Endoscopic management of combined biliary and duodenal obstruction. Clin Endosc 2019; 52 (01) 40-46
99 Neuzillet C, Bouché O, Tournigand C. et al. Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): results from a prospective national randomized GERCOR trial. J Clin Oncol 2022; 40 (16, Suppl): 4007-4007
100 Florez Bedoya CA, Cardoso ACF, Parker N. et al. Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. Sci Rep 2019; 9 (01) 13966
101 Kurz E, Hirsch CA, Dalton T. et al. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell 2022; 40 (07) 720-737.e5
102 Brennan GT, Saif MW. Pancreatic enzyme replacement therapy: a concise review. JOP 2019; 20 (05) 121-125
103 Sheffield KM, Boyd CA, Benarroch-Gampel J, Kuo YF, Cooksley CD, Riall TS. End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer 2011; 117 (21) 5003-5012

Zusatzmaterial

Supplementary Material (PDF)